Interview with Swee-Yeok CHU, CEO & President, EDBI/Bio One Capital
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Address: 250 North Bridge Road,#28-00 Raffles City Tower, Singapore 179101,Singapore
Tel: +65 6832 6832
Web: http://www.edbi.com/
Bio One Capital is a leading strategic investment firm headquartered in Singapore with a worldwide presence investing to drive growth opportunities within the knowledge and innovation-intensive sectors of Biomedical Sciences, Clean Technologies, Internet & Digital Media, as well as other strategic industry clusters with commercial potential. As a value adding investor, they create sustainable and synergistic partnerships with their portfolio companies, leveraging on their broad network of resources and experience to facilitate the companies’ organic growth in Asia and the world, through their operations in Singapore
Investment firm
As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm…
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the challenges of introducing cutting-edge cell and gene therapies, how the company works with regulators and payers…
Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards…
Novo Nordisk Singapore’s Praful Chakkarwar explains how he leverages his experience in a range of geographies in his current role, how COVID-19 has helped facilitate the affiliate’s digital transformation, the…
Nawal Roy of global digital health platform Holmusk which aims to establish data as a core utility to the treatment of behavioural health disorders explains the challenges of working in…
ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead…
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region, outlines the impact of Singapore’s status as a…
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems…
Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the…
MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more…
In an exclusive and wide-ranging interview, Harjit Gill outlines the work of pan-Asia-Pacific medtech association APACMed, how COVID-19 represents a chance to change the global narrative on medtech in healthcare,…
Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue…
See our Cookie Privacy Policy Here